1. Home
  2. PVLA vs AMBI Comparison

PVLA vs AMBI Comparison

Compare PVLA & AMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PVLA
  • AMBI
  • Stock Information
  • Founded
  • PVLA 2015
  • AMBI 1995
  • Country
  • PVLA United States
  • AMBI Brazil
  • Employees
  • PVLA N/A
  • AMBI N/A
  • Industry
  • PVLA Biotechnology: Pharmaceutical Preparations
  • AMBI Environmental Services
  • Sector
  • PVLA Health Care
  • AMBI Industrials
  • Exchange
  • PVLA Nasdaq
  • AMBI Nasdaq
  • Market Cap
  • PVLA 308.2M
  • AMBI 282.3M
  • IPO Year
  • PVLA N/A
  • AMBI N/A
  • Fundamental
  • Price
  • PVLA $24.36
  • AMBI N/A
  • Analyst Decision
  • PVLA Strong Buy
  • AMBI
  • Analyst Count
  • PVLA 7
  • AMBI 0
  • Target Price
  • PVLA $44.43
  • AMBI N/A
  • AVG Volume (30 Days)
  • PVLA 97.9K
  • AMBI 14.0K
  • Earning Date
  • PVLA 05-15-2025
  • AMBI 01-01-0001
  • Dividend Yield
  • PVLA N/A
  • AMBI N/A
  • EPS Growth
  • PVLA N/A
  • AMBI 250.01
  • EPS
  • PVLA N/A
  • AMBI 0.16
  • Revenue
  • PVLA N/A
  • AMBI $582,477,596.00
  • Revenue This Year
  • PVLA N/A
  • AMBI N/A
  • Revenue Next Year
  • PVLA N/A
  • AMBI N/A
  • P/E Ratio
  • PVLA N/A
  • AMBI $26.16
  • Revenue Growth
  • PVLA N/A
  • AMBI 27.80
  • 52 Week Low
  • PVLA $6.20
  • AMBI $3.07
  • 52 Week High
  • PVLA $29.27
  • AMBI $8.20
  • Technical
  • Relative Strength Index (RSI)
  • PVLA N/A
  • AMBI 41.31
  • Support Level
  • PVLA N/A
  • AMBI $4.17
  • Resistance Level
  • PVLA N/A
  • AMBI $4.45
  • Average True Range (ATR)
  • PVLA 0.00
  • AMBI 0.47
  • MACD
  • PVLA 0.00
  • AMBI -0.09
  • Stochastic Oscillator
  • PVLA 0.00
  • AMBI 15.00

About PVLA Palvella Therapeutics Inc. Common Stock

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.

About AMBI Ambipar Emergency Response

Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.

Share on Social Networks: